Cambridge, UK, 12th May 2022 / Sciad Newswire / Domainex Ltd, a leading integrated medicines research services partner, is pleased to announce that Dr Scott Martin has been appointed Analytical and Bioanalytical Group Leader with immediate effect. His appointment will strengthen Domainex’s rapidly expanding team of international scientists and follows the announcement of Domainex’s purchase of over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays.
“I am delighted to join Domainex,” said Dr Martin. “I’m looking forward to leading the expanding team and creating innovative solutions to develop new services and capabilities and optimising our existing offerings. The newly equipped labs have everything the team needs and will be a great place to work.”
Dr Martin has 25 years of experience in bioanalytical/analytical mass spectrometry within drug discovery and development, predominately gained in large pharma. He has successfully supported projects throughout the drug discovery and development process by driving scientific innovation, matrix managing teams and providing expert opinion in the fields of biotransformation and bioanalysis. Before joining Domainex, Dr Martin worked for AstraZeneca for 20 years as an associate principal scientist within the Oncology DMPK department. Previously, he has held positions in analytical/bioanalytical science at Roche, GlaxoWellcome, Zeneca Agrochemicals and a large contract research organisation (CRO).
“I’m thrilled to welcome Scott to Domainex,” commented Dr Tom Mander, CEO of Domainex. “His wealth of experience will be invaluable in helping Domainex further strengthen its analytical chemistry and bioanalytical team. The team is expanding rapidly, and Scott’s experience makes him the ideal candidate to guide the group during this exciting period of growth. So far this year, 16 recruits have joined the Domainex team, and I would like to take this opportunity to welcome these new staff members.”
Notes to Editors
About Domainex Ltd.
Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.
Domainex provides innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for its partners’ research. Domainex’s innovative science and extensive technical capabilities enable it to produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects.
Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. The Company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.
Full information about Domainex and its award-winning services can be found at www.domainex.co.uk.
For more information, please contact:
Dr. Tom Mander, CEO
Deborah Cockerill / Jasmin Shearan / Darya Shulakova
T: +44 (0)20 3405 7892